Lipoprotein (a), C-reactive protein and some metabolic cardiovascular risk factors in type 2 DM by Ogbera, Anthonia O & Azenabor, Alfred O
RESEARCH Open Access
Lipoprotein (a), C-reactive protein and some
metabolic cardiovascular risk factors in type 2 DM
Anthonia O Ogbera
1,2*, Alfred O Azenabor
3
Abstract
Background: Lipoprotein (a) (LP (a) is an independent cardiovascular risk factor that is not widely studied in
people of sub-Saharan African origin. The aim of this report is to determine the frequency of occurrence of
elevated Lp (a) and possible relationship with total cholesterol (TCHOL), high density lipoprotein cholesterol (HDL-
C), low density lipoprotein cholesterol (LDL-C), triglycerides (TG), C reactive protein (CRP) and serum uric acid (SUA).
Methods: This is a cross sectional study carried out in 200 Nigerian patients with type 2 DM and 100 sex and age
matched healthy Controls aged between 32-86 years. We determined the frequency of occurrence of elevated Lp
(a) levels in the study subjects and compared clinical and biochemical variables between type 2 diabetic patients
and non-diabetic patients. Clinical and biochemical parameters were also compared between subjects with type 2
DM who had elevated LP (a) and normal LP (a) levels. Long term glycaemic control using glycosylated
haemoglobin was determined and compared in the study subjects. Test statistics used include chi square,
correlation coefficient analysis and Student’s t test.
Results: The mean Lp(a) concentration differed significantly between type 2 diabetic patients and the Control
subjects (18.7 (5.8) mg/dl vs 23 (6.8) mg/dl, 0.00001). Similarly, the prevalence of high LP (a) levels in type 2 DM
patients was significantly higher than that of the Control subjects (12.5% vs 4%, p-0.019). The mean levels of the
lipid profile parameters (TCHOL, LDL-C, TG, LDL/HDL) and CRP were significantly higher in DM patients than in the
Control subjects. The mean LP (a) levels were comparable in both sexes and in DM subjects with and without
hypertension. TG was the only parameter that differed significantly between subjects with elevated Lp (a) levels
and those with normal Lp (a) levels. There was a significant positive correlation (r) between Lp(a) levels and TG,
LDL-C. TCHOL, LDL/HDL and uric acid. No association was found between Lp(a) and clinical parameters such as
age and anthropometric indices.
Conclusion: We have showed that Lp (a), CRP and other CVS risk factors cluster more in patients with DM than
non DM patients. Serum Lp (a) levels are not associated with anthropometric and glycaemic indices.
Background
Diabetes mellitus is a chronic metabolic disorder that is
often associated with unacceptably high disease burden
especially in developing countries [1] and cardiovascular
(CVS) complications of DM are highly contributory to
this scenario. Well studied and documented CVS risk
factors in DM include components of the metabolic syn-
drome namely reduced high density lipoprotein choles-
terol and reduced triglyceride levels, central obesity and
hypertension [2]. Other CVS risk factors that have not
been widely studied in African populations include
elevated C-reactive protein, hyperuricaemia and high
lipoprotein a levels. Lipoprotein(a) [Lp(a)] consists of an
LDL-like particle and the specific apolipoprotein(a) [apo
(a)], which is covalently bound to the apoB of the LDL
like particle [3]. Elevated levels of Lipoprotein a (Lp (a)
)a r ef o u n dt ob ei n d e p e n d e n tr i s kf a c t o r sf o rc o r o n a r y
heart disease. The structure of Lp(a) resembles LDL and
its atherogenic properties can be explained by its bind-
ing to glycosaminoglycans and inhibition of fibrinolysis
[4]. The atherogenic properties of Lp(a) are expressed
over 30 mg/dL serum concentration [4]. Some reports
on serum Lp (a) levels in subjects with type 2 DM show
that Lp (a) levels are higher in this group of patients
compared with non diabetic healthy controls [5,6].
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to reflect not only the inflammatory status in type 2
DM but also are associated with other indicators of dia-
betes-related cardiovascular risk[7]. Elevated serum uric
acid (SUA) levels have been associated not only with the
components of the Mets [8] but also found to be predic-
tors of cardiovascular diseases in non diabetic patients
and those with type 2 diabetes [9,10].
The aim of this report is to determine the frequency
and pattern of occurrence of Lp (a) levels in subjects
with type 2 DM. Other objectives include comparing the
biochemical and clinical parameters of the subjects with
t y p e2D Mw h oh a de l e v a t e dL p{ a )l e v e l sa n dt h o s e
without elevated Lp (a) levels.We also sought to deter-
mine the prevalence of elevated CRP and SUA levels in
subjects with type 2 DM.
Methods
This study was carried out at the Diabetes Centre of the
Lagos State University Teaching Hospital, Ikeja, Lagos
State, Nigeria for a period of three months. A total of
two hundred patients with type 2 DM and a hundred
healthy age and sex matched individuals were recruited
as the Control group. Inclusion criteria for subjects with
type 2 DM included patients who were treatment naïve
for dyslipidaemia. Exclusion criteria for the subjects
with type 2 DM included acutely ill patients requiring
hospitalization, those with renal failure or already on
dialysis.
The study subjects underwent clinical examination
that included anthropometric measurements. The
anthropometric measurements comprised of waist cir-
cumference, height and body weight, and the body mass
index (BMI) was calculated as weight/height
2 (kg/m
2).
Waist circumference was determined by applying a tape
measure to the midpoint between the inferior margin of
the last rib and the crest of the ilium.
Biochemical analyses-The DM free status of the con-
trols was ascertained by having them subjected to glyco-
sylated hemoglobin test. They were considered to be
non diabetic if their glycosylated haemoglobin levels
were less than 6.5%.
The Controls and the subjects with type 2 DM all had
some biochemical tests done and these included glyco-
sylated haemoglobin (HbA1c), fasting lipid profile and
blood glucose, uric acid and CRP. Lipids, blood glucose
and uric acid were analysed spectrophotometrically. The
name and model of the spectrophotometer used are
SSRFI and BSA 3000.
Lipid: Total cholesterol was determined using a modi-
fied method of Liebermann-Burchard [11], HDL-choles-
terol by precipitation method [12] and TG was
estimated using a kit employing enzymatic hydrolysis of
TG with lipases [13]. The Friedwald’sf o r m u l a[ 1 4 ]L D L
= (TCHOL - HDL-C) - TG/5 was used to determine
LDL-C when the values of TG were less than 400 mg%
and LDL-C/HDL-C ratios were calculated. Plasma glu-
cose was measured using the glucose oxidase method
[15] and uric acid was measured on a standard
autoanalyzer.
Glycosylated haemoglobin level was determined as a
point of care test using capillary samples with the
Biorad equipment.
CRP and Lp(a) levels were determined using immuno
turbidimetric methods.
The intra-assay CVs for SUA, Lp (a) and CRP were
1.66%, 1.68% and .1.52% respectively and the inter-assay
CVs were 1.81%, 1.14%, 1.84% and 1.72% respectively.
Working diagnosis
Elevated Lp (a) levels refer to serum levels above 30 mg/
dl [4]
Elevated CRP levels refer to levels above 3 mg%[16].
Hyperuricaemia or elevated SUA levels refer to serum
u r a t el e v e l so f>6m g / d li nw o m e na n d>7m g / d li n
men [17].
Statistical Analysis
Data were analyzed using SPSS version 17. Student’s test
was used to compute the mean levels of continuous
variables and also to make comparison of these continu-
ous variables between different groups. Pearson correla-
tion coefficient determination was done to evaluate the
degree of association between Lp(a ) and clinical and
biochemical parameters. Chi square analysis was used to
compare proportions. Quantitative data are expressed as
mean and standard deviation (SD). P values of < 0.05
were considered to be statistically significant.
Results
The mean age and standard deviation (SD) of the
patients with type 2 DM was 57.7 (10.8) years and the
female: male ratio was 134:66. The age range was 32-86
years. The mean and (SD) BMI and waist circumference
of the subjects with type 2 DM was 29.7 (7.5) and 93
(12,4) respectively. The mean age (SD) of the Controls
was 56.1 (11.2) years and this was comparable to that of
the subjects with type 2 DM (p-0.8). A total number of
103 of the subjects with type 2 DM had a history of
hypertension thus making up 52% of the population.
A summary of some clinical and biochemical parameters
in subjects with type 2 DM
The mean levels of some clinical and biochemical para-
meters of the subjects with type 2DM are shown in
table 1.
The mean levels of Lp (a) in the subjects with type 2
DM were higher than those of the Control subjects and
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dl vs 23 (6.8) mg/dl, p-0.00001). The mean Lp (a ) levels
in both sexes were however comparable (males vs
females-22.9 (6.8) mg/dl vs 23.1 (6.7) mg/dl p-0.8. In
subjects with and without hypertension the mean Lp (a)
levels were also comparable (23 (6.7)mg/dl; vs 23 (6.8)
mg/dl p-0.7). The prevalence of elevated Lp (a) levels in
the subjects with type 2 DM was 12.5% and in the Con-
trol subjects was 4% and this difference was statistically
significant, p-0.019. The majority of the study subjects
had Lp(a) levels in the range of 20-30 mg/dl and a sum-
mary of these results are shown in Figure 1. A compari-
son of the distribution of the various categories of the
Lp (a) levels showed that the proportion of the subjects
with type 2 DM who had levels of Lp (a) greater than
20 mg/dl was greater than that of the Control subjects.
(These results are shown in Figure 2). All studied bio-
chemical parameters other than HDL-C were signifi-
cantly higher in subjects with type 2 DM compared to
the Control subjects. These results are shown in Table
2. A comparison of the mean levels of the biochemical
parameters studied between type 2 DM subjects with
elevated Lp (a) and those with normal Lp (a) levels
showed that these two groups of subjects differed only
in their TG levels. These results are shown in Table 3.
Correlation analysis of Lp (a) and various parameters
showed that Lp (a) was significantly correlated with
some lipid parameters but had no significant association
with glycosylated haemoglobin. These results are shown
in Table 4. The pattern of distribution of CVS risk fac-
tors in the subjects with type 2 DM showed that uric
acid and CRP were documented in 59% and 63% respec-
tively of them. These results are depicted in Figure 3.
Discussion
We report the overall prevalence rate of elevated Lp (a)
in the study subjects, patients with type 2 DM and the
Control subjects to be 10.5%, 12.5% and 4% respectively.
Unlike our findings, thoseb yS c e r t h a n e re ta l[ 1 8 ] ,
noted that Lp (a) levels were comparable in subjects
with DM and healthy Controls. Their findings may be
attributed to the non-homogeneous nature of their
study population which essentially was made up of sub-
jects with types 1 and 2 DM. Many reports on Lp (a)
levels however indicate higher prevalence rates of ele-
v a t e dL p( a )i np e o p l ew i t ht y p e2D Mc o m p a r e dt o
healthy non diabetic subjects and type 1 DM patients
[5,6,19]. Our reported prevalence rate of elevated Lp (a)
is much lower than that by Habib et al [6] who reported
Table 1 Clinical and biochemical parameters of subjects
with type 2 DM
Variable Mean(SD) Range
BMI(Kg/m2) 28.6(5.9) 15-57
WC(cm) 93.1(12.4) 59-140
*DDM (years) 6(5.9) 0.1-9
HbA1c(%) 6.3(2.4) 4-14
FBS(mg%) 163(70) 43-301
*duration of DM
Figure 1 Distribution of Lp (a) in the study subjects.
Figure 2 Comparison of Lp (a) levels in type 2 DM subjects
and Control subjects.
Table 2 Comparison of some biochemical parameters in
subjects with type 2 DM and the Control subjects
Variable Control subjects Type 2 DM p
HbA1c(%) 5(1.0) 6(2.3) 0.00001
TChol (mg%) 190.2(71.7) 314(52.8) 0.009
TG (mg%) 144.72(71.7) 300 (50.8) 0.007
HDL-C(mg%) 48.4(10) 41.8(14.7) 0.001
LDL-C(mg%) 123.5(20) 132(41.3) 0.04
LDL-C/HDL-C 2.6(0.7) 3.6 (1.8) 0.00001
CRP(mg%) 3.5(21) 9.2(13) 0.00001
SUA (mg/dL) 7.2(2.2) 7.2(2.8) 0.8
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is of note that elevated serum TG is a prominent feature
of patients with type 2 DM who have elevated Lp (a)
levels and this is evident by the results we obtained
when we compared biochemical and clinical parameters
between type 2 DM patients with elevated LP (a) levels
and those with normal Lp (a) levels. Some studies how-
ever have shown that CRP is not only a significant cor-
r e l a t eo fL p( a )b u ta l s os u g g e s tt h a ti tm i g h tb eo f
clinical value in identifying individuals whose serum Lp
(a) levels are transiently or chronically increased [20].
We have noted in this report that serum LP (a) had no
significant correlation with CRP, but is significantly
associated with other CVS risk factors namely, LDL-C,
LDL/HDL, uric acid and TG. The findings by Heller et
al[5] and Habib [6] differ somewhat from ours in that
they report a positive correlation of Lp(a) with total
cholesterol and LDL-C but not with triglycerides and
HDL-C. We have also shown in this study that over half
of our patients with type 2 DM have elevated CRP,
LDL-C, SUA and reduced HDL-C levels. It is instructive
to note that except for SUA, the mean serum levels of
all the studied biochemical parameters (TCHOL, TG,
HDL, LDL-C and LDL/HDL, CRP) differed significantly
between the Control subjects and the subjects with type
2 DM. Hypertension a CVS risk factor and metabolic
syndrome defining criterion is a commonly documented
co-morbidity of DM in Nigerians [21,22]. We have
found in this study, that the presence of hypertension
did not affect Lp (a ) levels in DM subjects with and
without hypertension. In an earlier Nigerian study [19],
subjects with hypertensive-diabetes mellitus had signifi-
cantly worse lipid and lipoprotein (a) profiles compared
with subjects with diabetes mellitus or hypertension
only. Although not stated as part of the objective of this
study, a cursory assessment of our results showed that
t h ep r e s e n c eo fe l e v a t e dL p( a )l e v e l sh a dn ob e a r i n g
with glycaemic control and the mean HbA1c levels were
comparable in DM patients with and without elevated
Table 3 Comparison of some clinical and biochemical parameters in subjects with normal and elevated Lp (a) levels
Parameter Subjects with elevated Lp(a) levels Subjects with normal elevated Lp(a levels) p
HbA1c(%) 5.8(1.8) 6.4(2.4) 0.2
TChol (mg%) 209.5 (49) 196.4 (41.8) 0.1
TG (mg%) 144.72(71.7) 101 (52.8) 0.009
HDL-C(mg%) 38(14) 42.4(14.7) 0.1
LDL-C(mg%) 142.4(45.9) 130(40.6) 0.1
FBS(mg%) 166(79) 169(69.2) 0.8
CRP(mg% ) 15.1 (24.1) 13.4(10.8) 0.9
SUA (mg/dL) 7.2(2.2) 7.2(2.8) 0.8
WC(cm) 95.8(13.7) 92.7(12.1) 0.2
BMI(Kg/m2) 29.3(7.3) 28.5(5.6) 0.5
DDM(years) 5.9(4.9) 6.1(6.1) 0.9
Age(years) 59.9(11.4) 57.2(10.3) 0.3
Table 4 Correlation (r) between LP (a) and some clinical
and biochemical parameters
Variable r p
TG 0.2 0.007
HDL-C -0.1 0.1
LDL-C 0.14 0.03
LDL-C/HDL-C 0.15 0.02
TCHOL 0.2 0.01
SUA 0.14 0.04
CRP 0.2 0.7
HbA1c -0.01 0.5 Figure 3 Prevalence of cardiovascular risk factors in type 2 DM.
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similar results with our findings on the relationship
between glycaemic control and Lp (a). In these studies
[19,20,23] there was found no relation between HbA1c
and Lp(a) concentrations in subjects with type 1 and 2
DM.
Conclusion
Elevated serum Lp (a) levels are higher in subjects with
DM than in people without DM but comparable in DM
patients with and without hypertension. Serum LP (a) is
significantly and positively associated with most of the
atherogenic profile defining parameters in type 2 DM of
which elevated TG is prominent.
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